Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gabriel D DePinho"'
Autor:
Caron Jacobson, Matthew J Frigault, Nora Horick, Areej R El-Jawahri, Kevin Lindell, Dustin J Rabideau, P Connor Johnson, Alisha Yi, Mahmoud R Gaballa, Gabriel D DePinho
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Chimeric antigen receptor (CAR) T-cell therapy recipients may receive bridging therapy while awaiting product manufacturing to control disease. Yet, data are lacking regarding the impact of bridging therapy use on clinical outcomes.Methods
Externí odkaz:
https://doaj.org/article/e2c29abb29b847ad9400146f5ffa24b3
Autor:
Matthew J. Frigault, Jorg Dietrich, Kathleen Gallagher, Mark Roschewski, Justin T. Jordan, Deborah Forst, Scott R. Plotkin, Daniella Cook, Keagan S. Casey, Kevin A. Lindell, Gabriel D. Depinho, Katelin Katsis, Eva Lynn Elder, Mark B. Leick, Bryan Choi, Nora Horick, Frederic Preffer, Meredith Saylor, Steven McAfee, Paul V. O’Donnell, Thomas R. Spitzer, Bimalangshu Dey, Zachariah DeFilipp, Areej El-Jawahri, Tracy T. Batchelor, Marcela V. Maus, Yi-Bin Chen
Publikováno v:
Blood
CD19-directed chimerical antigen receptor T-cell (CAR-T) products have gained US Food and Drug Administration approval for systemic large B-cell lymphoma. Because of concerns about potential immune cell-associated neurotoxicity syndrome (ICANS), pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d2f9678c2fb9631e49505e413843d56
https://pubmed.ncbi.nlm.nih.gov/35420689
https://pubmed.ncbi.nlm.nih.gov/35420689
Autor:
P Connor Johnson, Caron Jacobson, Alisha Yi, Mahmoud R Gaballa, Nora Horick, Dustin J Rabideau, Kevin Lindell, Gabriel D DePinho, Areej R El-Jawahri, Matthew J Frigault
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004567
BackgroundChimeric antigen receptor (CAR) T-cell therapy recipients may receive bridging therapy while awaiting product manufacturing to control disease. Yet, data are lacking regarding the impact of bridging therapy use on clinical outcomes.MethodsW
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b1b7fca8e54864269b115d6f28e941b
https://doi.org/10.1136/jitc-2022-004567
https://doi.org/10.1136/jitc-2022-004567
Autor:
Matthew J. Frigault, Jacalyn Rosenblatt, Daniella Cook, Ha Na Cho, Gabriel D. Depinho, Emma Logan, Jessica Liegel, Yougeesh Prabhakar, Christine Cornwell, Kamalika Banerjee, Anand Rotte, Christopher Ryan Heery, David Avigan, Andrzej J. Jakubowiak, Michael Russell Bishop
Publikováno v:
Journal of Clinical Oncology. 40:8003-8003
8003 Background: Chimeric Antigen Receptor (CAR) T cell therapies targeting B-cell maturation antigen (BCMA) have demonstrated benefit in patients (pts) with relapsed and/or refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4548b90357987857c24d12046aa03edf
https://doi.org/10.1200/jco.2022.40.16_suppl.8003
https://doi.org/10.1200/jco.2022.40.16_suppl.8003